ScholarLens Back to search
2000•European Journal of Nuclear Medicine and Molecular ImagingRequires access

Phase I/II 90 Y-Zevalin (yttrium-90 ibritumomab tiuxetan, IDEC-Y2B8) radioimmunotherapy dosimetry results in relapsed or refractory non-Hodgkin's lymphoma

Gregory A. Wiseman, Christine A. White, Michael Stabin, William L. Dunn, William D. Erwin, Magnus Dahlbom, Andrew Raubitschek, Kastytis C. Karvelis, Timothy E. Schultheiss, Thomas E. Witzig, Richard E. Bélanger, Stewart Spies, Daniel Silverman, Judy Berlfein, Eric Ding, Antonio J Grillo-López

Open publisher page 234 citations

Abstract

This record does not include an abstract. Use the full-text link above if available.

About this research paper

What this paper is about

An abstract is not available in the OpenAlex record for this paper.

Why it matters

OpenAlex reports 234 citations for this work. Citation counts describe recorded attention and do not establish research quality.

Key contribution

A contribution statement is not available in the OpenAlex record.

Method / approach

Method details are not available in the OpenAlex metadata.

Main findings

Findings are not separately available in the OpenAlex metadata.

Limitations

Limitations are not available in the OpenAlex metadata.

Applications

Application details are not available in the OpenAlex metadata.

Key concepts: Ibritumomab tiuxetan, Radioimmunotherapy, Medicine, Nuclear medicine, Dosimetry, Bone marrow, Rituximab, Lymphoma

Related papers

Related paper 1Related paper 2Related paper 3
Back to paper searchBrowse research topicsOriginal source
Phase I/II 90 Y-Zevalin (yttrium-90 ibritumomab tiuxetan, IDEC-Y2B8) radioimmunotherapy dosimetry results in relapsed or refractory non-Hodgkin's lymphoma — Research Paper | ScholarLens